Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial

Autor: Frigault, Matthew J, Dietrich, Jorg, Gallagher, Kathleen, Roschewski, Mark, Jordan, Justin T, Forst, Deborah, Plotkin, Scott R, Cook, Daniella, Casey, Keagan S, Lindell, Kevin A, Depinho, Gabriel D, Katsis, Katelin, Elder, Eva Lynn, Leick, Mark B, Choi, Bryan, Horick, Nora, Preffer, Frederic, Saylor, Meredith, McAfee, Steven, O'Donnell, Paul V, Spitzer, Thomas R, Dey, Bimalangshu, DeFilipp, Zachariah, El-Jawahri, Areej, Batchelor, Tracy T, Maus, Marcela V, Chen, Yi-Bin

Publikováno v: Blood; 20220101, Issue: Preprints

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Autor: Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Vatsa S; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Lindell KA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Demato A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

Publikováno v: Blood cancer discovery [Blood Cancer Discov] 2022 Mar 01; Vol. 3 (2), pp. 136-153.